| 8.42 -0.28 (-3.22%) | 10-30 14:32 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.76 | 1-year : | 12.57 |
| Resists | First : | 9.22 | Second : | 10.76 |
| Pivot price | 7.97 | |||
| Supports | First : | 7.89 | Second : | 7.07 |
| MAs | MA(5) : | 8.15  |
MA(20) : | 8.06 |
| MA(100) : | 6.51 |
MA(250) : | 5.5  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 66.6 |
D(3) : | 53.6 |
| RSI | RSI(14): 56 |
|||
| 52-week | High : | 11.92 | Low : | 2.58 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ XGN ] has closed below upper band by 27.1%. Bollinger Bands are 20.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.88 - 8.91 | 8.91 - 8.94 |
| Low: | 8.25 - 8.29 | 8.29 - 8.33 |
| Close: | 8.64 - 8.69 | 8.69 - 8.74 |
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
Thu, 29 Oct 2026
Exagen Inc. to Participate in Upcoming Investor Conferences - The Manila Times
Tue, 27 Oct 2026
Exagen to Announce Third Quarter Financial Results on November 10, 2026 - The Manila Times
Fri, 23 Oct 2026
Exagen Inc. Estimates – NASDAQ:XGN - TradingView
Tue, 20 Oct 2026
10% Owner Jorey Chernett Buys 14,000 Shares of Exagen Inc (XGN) - GuruFocus
Wed, 05 Aug 2026
Exagen: The Path To Profitability Just Became More Credible (NASDAQ:XGN) - Seeking Alpha
Tue, 04 Aug 2026
Exagen (XGN) Stock Jumps On Record Revenue But Profit Timing Remains Unclear - Simply Wall Street
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 24 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 24.2 (%) |
| Held by Institutions | 44.9 (%) |
| Shares Short | 705 (K) |
| Shares Short P.Month | 864 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.5 |
| Profit Margin | -26.7 % |
| Operating Margin | -8.7 % |
| Return on Assets (ttm) | -15 % |
| Return on Equity (ttm) | -113.9 % |
| Qtrly Rev. Growth | 15.8 % |
| Gross Profit (p.s.) | 1.72 |
| Sales Per Share | 2.93 |
| EBITDA (p.s.) | -0.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -10.4 |
| PEG Ratio | 0 |
| Price to Book value | 16.84 |
| Price to Sales | 2.86 |
| Price to Cash Flow | -31.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|